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ABSTRACT
Objective: The purpose of this study was to analyze the assortment, availability, consumption status, and dynamics of lipid-lowering drugs in the 
pharmaceutical market in Ukraine.
Methods: Among the primary methods of research were applied the following: System and content analysis, marketing, logical and mathematical 
analysis, graphical mode, and also a way of detailed and abstract simulation and synthesis.
Results: The ratio of imported and domestic lipid-lowering drugs in Ukrainian pharmaceutical market was analyzed (imported lipid-lowering 
medicines account for 82% of the total number of this group in Ukrainian market, the share of local medications is 18%, respectively). The structural 
review and analysis of market characteristics of 5-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors group of medicines (sales, accessibility 
for people, and competitiveness) were conducted, and the most promising market segment for producers and distributors was identified. The most 
promising sector is rosuvastatin, which is characterized by an average sales volume with a tendency to increase and a high increasing profit.
Conclusion: Data on dynamics of the development of lipid-lowering drugs segment in the pharmaceutical market of Ukraine are systematized, which 
enables potential manufacturers to identify their market niche. As a result of the study, heavy dependency on imported lipid-lowering drugs in the 
pharmaceutical market of Ukraine was established, which determines low economic accessibility (especially in case of increasing in exchange rates) 
and physical availability (dependence on the regularity of shipments to Ukraine) for consumers. The most competitive medicines of atorvastatin and 
rosuvastatin group were determined, it was established that sales leader was pharmaceutical company KRKA dd, Novo Mesto (Slovenia) with generics 
Atoris and Roxer.
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INTRODUCTION
It is common knowledge that cardiovascular diseases (CVDs) are the 
leading causes of death and disability in the world (more than 17 
million deaths per year) [1,2].
The World Health Organization data indicate that CVDs, primarily 
stroke and coronary heart disease (CHD), are responsible for the death 
rate of about 48% of Europeans. At the same time, Ukraine has the 
most unfavorable dynamics of indicators and, to date, ranks first among 
European countries regarding mortality from circulatory system 
diseases and strokes [3,4].
Of particular, concern is the fact that more than 426,000 Ukrainians 
die annually from CVDs (an average of about 1000 people die daily). 
In the total mortality of Ukrainians over the past 3 years, CVDs account 
for 66% (in 2016, this figure was 67.3%), while in most European 
countries, this number does not exceed 50%. For example, the death 
rate in Ukraine due to a stroke in men is 18 times, and in women 
14 times higher than in Switzerland [4].
According to numerous studies, almost 85% of CVDs develop as a 
result of circulatory disorders, which most often occur due to the 
accumulation of cholesterol in the duct of vessels (atherosclerosis). 
The lipid-lowering drugs prevent deposits of cholesterol plaques 
in the duct of vessels, thereby reducing the risk of many diseases, in 
particular, inhibitors of 5-hydroxy-3-methylglutaryl-coenzyme A 
(HMG-CoA) reductase (statins), whose high efficacy and safety have 
been demonstrated in some long-term multicentered studies [3,5-7].
In the global drugs market, it is the inhibitors of HMG-CoA reductase 
is the leaders in sales in recent years. It is explained by the fact that 
statin therapy is considered as a long-term strategy for primary and 
secondary prevention of CVDs and severe ischemic cases (sudden 
coronary death, myocardial infarction, and stroke) [7,8].
Ukraine is a part of the international community of countries that 
have set a goal to decrease mortality from CVDs by 25% in 2025. In 
this direction, in our opinion, the importance of educational work is 
unconditional, but the presence on Ukrainian pharmaceutical market 
a sufficient number of highly efficient and simultaneously available 
medicines, particularly lipid-lowering drugs, is an equally important 
component of timely medical and pharmaceutical assistance.
The purpose of our work was to analyze the medicines of the GMC-CoA 
reductase group of inhibitors in pharmaceutical market of Ukraine.
The rationale of the study dictates the need for accessibility of statins 
for patients who need lipid-lowering therapy, on the one hand, and 
providing information on market and demand trends for inhibitors of 
GMC-CoA reductase medications of local and foreign manufacturers, on 
the other hand.
It is known that the concept of social and ethical aspects of marketing is 
the most acceptable by the pharmaceutical industry, based on balancing 
three factors: Buyers (satisfaction of needs), enterprise (profit), and 
society (ensuring the continued welfare of the community as a whole). 
It is one of the fundamental principles of marketing management of a 
pharmaceutical enterprise to form the range of medicines following 
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needs of consumers [9]. Consequently, organized data on dynamics of 
the development of lipid-lowering drugs segment in pharmaceutical 
market of Ukraine enable potential manufacturers to identify their 
market niche.
The novelty of the study is a definition of competitiveness coefficient 
for trade names of medicines, characterizing the level of trust between 
doctors and consumers toward specific drugs and their manufacturers 
in dynamics.
METHODS
During the study, we used data from the information retrieval system 
Medicines State Register of Ukraine and the directory Compendium 
2017 - Medicines [10,11].
Morion Company data (sales of medicines for 2013–2015) were used 
while analyzing the life cycle and computation of competitiveness.
Among the significant methods of research were the following: System 
and content analysis (study of local and foreign publications on the 
problem of circulatory system diseases, statistical data); marketing, 
logical, and mathematical analysis (analysis of drug market structure, 
definition of competitiveness); graphical method (visual, schematic 
representation of research results), as well as a process of descriptive 
and abstract simulation and generalization (formulation of conclusions).
RESULTS AND DISCUSSION
At the first stage of the study, it was found that the range of lipid-lowering 
drugs (C10A) in Ukrainian pharmaceutical market is represented by 82 
trade names, taking into account dosage forms and without taking into 
account dosages (as of July 2017). The summarized data are presented 
in Table 1.
Among the groups of drugs with lipid-lowering effect, HMG-CoA 
reductase inhibitors are considered to be the most effective medicines, 
which are stable and significantly reducing the level of cholesterol and 
low-density lipoprotein, improving the clinical course of CHD, and 
reducing the risk of fatal and non-fatal myocardial infarction and total 
mortality [5-8,12].
The subgroup of HMG-CoA reductase inhibitors (C10AA) on the 
pharmaceutical market of Ukraine is represented by five international 
generic drugs, among them: Simvastatin (C10AA01), lovastatin 
(C10AA02), atorvastatin (C10AA05), rosuvastatin (C10AA07), and 
pitavastatin (C10AA08) (Fig. 1).
The next stage of the study was a structural analysis, which revealed 
that the group of simvastatin (excluding doses) in Ukrainian market is 
represented by 10 trade names of medicines produced in 10 countries 
(Great Britain, Jordan, India, the Kingdom of Saudi Arabia, Portugal, 
Macedonia, Serbia, Slovenia, Ukraine, and Czech Republic). It is 
noteworthy that a drug of Ukrainian production – Vasostat - health is 
only 10% of the total market share.
Atorvastatin (excluding dosages) is represented by 27 trade names 
from 11 countries (Israel, India, Canada, Malta, Poland, Republic of 
Macedonia, Slovakia, Slovenia, USA, Turkey, and Ukraine). Ukrainian 
drug manufacturers produce four drugs, which are 14.8% of the total, 
23 others are imported, which is 85.2%, respectively.
Rosuvastatin (excluding dosages) is represented by 24 trade names 
from 11 countries (UK, Hungary, Israel, India, Canada, Cyprus, Malta, 
Poland, Slovenia, Ukraine, and Czech Republic): 2 local drugs, which 
are 8.3% of the total, 22 others are imported, accounting for 91.7%, 
respectively.
Pitavastatin is represented by one imported medicine (France), 
lovastatin - 1 drug of Ukrainian origin.
Subgroups of fibrates (C10AB) and bile acid sequestrants (C10AC) are 
represented only by imported drugs (one each from Ireland and Canada, 
respectively); subgroup of other lipid-lowering agents (C10AX) - 2 
imported (Hungary, Netherlands) and 3 local; a subset of other drugs 
(C10AX19) - 1 imported (Hungary) and 3 local drugs.
Table 1: Lipid‑lowering drugs in the pharmaceutical market of Ukraine
International non‑proprietary name Number of 
medicines by trade 
names
Countries manufacturers
C10A Lipid-lowering drugs, monocomponent
C10A A HMG-CoA reductase Inhibitors
C10A A02 Lovastatin 1 Ukraine
C10A A01 Simvastatin 10 Great Britain, Jordan, India, Kingdom of Saudi Arabia, 
Portugal, Republic of Macedonia, Serbia, Slovenia, Ukraine, 
Czech Republic
C10A A05 Atorvastatin 27 Israel, India, Canada, Malta, Poland, Republic of Macedonia, 
Slovakia, Slovenia, USA, Turkey, Ukraine
C10A A07 Rosuvastatin 24 Great Britain, Hungary, Israel, India, Canada, Cyprus, Malta, 
Poland, Slovenia, Ukraine, Czech Republic
C10A A08 Pitavastatin 1 France
C10A B Fibrates
C10A B05 Fenofibrate 1 Ireland
C10A C Bile acid sequestrants
C10A C01 Colestyramine 1 Canada
C10A X Other lipid-lowering drugs
C10A X06 Omega-3-triglycerides including other 
esters and acids




C10B Lipid-lowering drugs, combination
C10B A HMG-CoA reductase inhibitors in combination with other lipid-lowering agents
C10B A02 Simvastatin and ezetimibe 1 Singapore
C10B A05 Atorvastatin and ezetimibe 2 India
C10B X HMG CoA reductase inhibitors, other combinations
C10B X03 Atorvastatin and amlodipine 5 Hungary, Germany, Malta, Slovenia, Ukraine
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Inhibitors of HMG-CoA reductase in combination with other lipid-
lowering agents (C10BA) are represented by three imported drugs 
(India, Singapore), and with other combinations (C10BX) 4 imported 
(Hungary, Germany, Malta, and Slovenia) and one local drug. The 
summarized data are presented in Table 2.
The next stage of our study was an in-depth life cycle analysis of the 
drug groups HMG-CoA reductase international nonproprietary name, 
as a model of the market reaction in time. It has been revealed that 
simvastatin medicines are at the stage of the recession, atorvastatin is 
at the saturation stage, and rosuvastatin is in the growth phase (Fig. 2).
The data obtained indicate a redistribution of proportions of inhibitors 
of GMC-CoA reductase medications in prescriptions. Since 2013, 
there has been an increase in the number of orders for rosuvastatin 
medications (therefore, an increase in their sales) and a decrease in 
the number of prescriptions for simvastatin drugs (as a consequence, 
sales). It is worth pointing out that the data of our study is consistent 
with results obtained by COMCON Pharma-Ukraine as the part of a 
regular research project “PrIndex (Prescription Index). Monitoring 
prescribing of medicines” [13].
Despite the decline in sales of atorvastatin drugs, they continue to 
occupy a leading position in the market, as evidenced by Ukrainian 
researchers and global trends [14,15].
At the next stage of the study, to determine the state and sustainability 
of demand for the drug group under consideration, we calculated the 
Fig. 1: Inhibitors of 5‑hydroxy‑3‑methylglutaryl‑coenzyme A reductase in the pharmaceutical market of Ukraine
Fig. 2: Sales volumes and life cycle drugs group of 5‑hydroxy‑3‑methylglutaryl‑coenzyme A reductase inhibitors in the pharmaceutical 
market of Ukraine
Fig. 3: Atorvastatin drugs are the leaders in sales in Ukrainian 
pharmaceutical market
competitiveness index, characterizing the level of attractiveness of 
OTC drugs for consumers, and the level of confidence in prescription 
medicines of doctors.
The calculation of competitiveness (C) was based on the drug sales 
volume (the number of packages was taken into account) in the period 
2013–2015 according to the formula:
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Where: V - The volume of drug sales, the competitiveness of which is 
calculated;
∑V - Sales of drugs competitor;
q - The number of drugs competitors.
Based on the results of the calculations, medicine’s groups of 
atorvastatin and rosuvastatin were identified as the most efficient, 
competitive, and safe (C >1). The summarized data are presented in 
Tables 3 and 4 and Figs. 3 and 4.
Based on the results of the analysis, it was revealed that only 6 out of 
the 27 trade names of the atorvastatin group registered in Ukraine 
are competitive. It was found that the most competitive drug from the 
atorvastatin group is Atoris (KRKA dd, Novo Mesto, Slovenia). Among 
other drugs, the coefficient of competitiveness of which is more than 
1, the following are distinguished: Atorvakor® (Pharmak, Ukraine), 
Torvacard® (Zentiva, Czech Republic), Livostor, (Kiev Vitamin Plant, 
Ukraine), Etset® (Kusum Pharm, Ukraine), and Atokor (Dr. Reddy’s Lab. 
Ltd, India). The summarized data are presented in Table 3 and Fig. 3.
Based on the results of the analysis, it was revealed that only 4 out of 
the 24 trade names of the rosuvastatin group registered in Ukraine 
are competitive. It has been established that the most competitive 
rosuvastatin drug is Roxera® (KRKA dd, Novo Mesto, Slovenia). Among 
other drugs, the coefficient of competitiveness of which is more than 
1, the following are distinguished: Rosart (Actavis Group, Iceland), 
Clivas (Pharma Start, Ukraine), and Crestor (AstraZeneca UK Limited, 
United Kingdom). The summarized data are presented in Table 4 and 
Fig. 4.
Competitiveness defines, on the one hand, qualitative characteristics of 
medicines, and on the other hand - all significant purchase conditions 
and further use for the consumer. The results show that in the treatment 
with lipid-lowering medication consumers prefer to use drugs of 
medium and high price range predominantly of European production.
CONCLUSION
As a result of the study, it was found that imported lipid-lowering 
medicines account for 82% (67 trade names) of the total number 
of drugs of this group in Ukrainian market and are represented by 
manufacturers from 24 countries (the share of local medicines is 18%, 
respectively). The existing situation indicates a high dependency on 
imports in this segment of Ukrainian pharmaceutical market and 
determines low economic and physical accessibility for consumers. 
It was discovered from the results of the analysis performed; the 
most competitive drugs of atorvastatin group are generics such as 
Atoris (Slovenia), Atorvakor (Ukraine), Torvacard (Czech Republic), 
Livostor (Ukraine), Etset (Ukraine), and Atokor (India). The most 
competitive medicines of rosuvastatin group are generics as Roxera 
(Slovenia), Rosart (Iceland), Clivas (Ukraine), and original medicine 
Crestor (Great Britain). The analysis found that in atorvastatin group 
of six competitive medicines two are of Ukrainian origin, which 
making a positive impact on the physical and economic availability 
of atorvastatin drugs. Moreover, in rosuvastatin group of nine drugs 
represented on the pharmaceutical market, only one is of Ukrainian 
origin that fact having a negative impact on the physical and 
economic accessibility of rosuvastatin group drugs to consumers. 
When analyzing market characteristics of drug groups, it has been 
established that the most promising segment is rosuvastatin, which is 
characterized by an average sales volume with a tendency to increase 
and a high increasing profit. The atorvastatin group is characterized 
by high sales but with a tendency to decrease and a top but declining 
profit. The simvastatin group is characterized by weak sales and low 
declining profits.
Table 2: Countries ‑ manufacturers of lipid‑lowering drugs in 
the Ukrainian market









Czech Republic 3 (3.66)
USA 2 (2.44)
Israel 2 (2.44)
United Kingdom 2 (2.44)
Macedonia 2 (2.44)
Portugal 1 (1.22)










Fig. 4: Rosuvastatin drugs are the leaders in sales in Ukrainian pharmaceutical market
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Table 3: Competitiveness of drugs with active substance 
atorvastatin in the pharmaceutical market of Ukraine 
(2013–2015)
Trade name Coefficients of competitiveness
1. 2. 3. To avg.
Atoris (Slovenia) 12.45 13.74 13.38 13.19
Atorvakor® (Ukraine) 2.08 3.37 3.53 2.99
Torvacard (Czech Republic) 2.32 2.2 2.29 2.27
Livostor (Ukraine) 2.83 3.4 0.48 2.24
Etset® (Ukraine) 1.64 2.25 2.54 2.14
Atokor (India) 1.21 1.2 1.23 1.21
Table 4: Competitiveness of medicines with active substance 
rosuvastatin in the pharmaceutical market of Ukraine 
(2013–2015)
Trade name Coefficients of competitiveness
1. 2. 3. To avg.
Roxera® (Slovenia) 3.08 2.42 2.45 2.65
Rosart (Iceland) 2.16 2.64 2.68 2.49
Clivas (Ukraine) 0.26 2.11 2.41 1.59
Crestor (United Kingdom) 1.67 1.03 1.13 1.28
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